{"protocolSection":{"identificationModule":{"nctId":"NCT06472921","orgStudyIdInfo":{"id":"202405104"},"organization":{"fullName":"Xiangya Hospital of Central South University","class":"OTHER"},"briefTitle":"Efficacy and Safety of Early Initiation of Butylphthalide Treatment in Patients With Acute Ischemic Stroke.","officialTitle":"Effect of Early Initiation of Butylphthalide on Neural Function in Patients With Acute Ischemic Stroke -A Prospective, Multicenter, Randomized, Open-label, Blinded End Trial"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-09-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-19","studyFirstSubmitQcDate":"2024-06-19","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-19","lastUpdatePostDateStruct":{"date":"2024-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xiangya Hospital of Central South University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is a prospective, multicenter, randomized, open-label, blinded-endpoint trial designed to evaluate the difference in efficacy of Butylphthalide Sodium Chloride Injection treatment initiated early (\\&lt;3 hours) versus late (3-6 hours) in patients with acute ischemic stroke. The aim is to determine the optimal timing window for neuroprotective therapy."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group and a late initiation group.\n\nEarly initiation group: Treatment with Butylphthalide Sodium Chloride Injection begins within 3 hours, administered at 100ml per dose, infused twice daily for a continuous period of 10-14 days.\n\nLate initiation group: Treatment with Butylphthalide Sodium Chloride Injection begins between 3-6 hours, also administered at 100ml per dose, infused twice daily for a continuous period of 10-14 days.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":200,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Early initiation group","type":"EXPERIMENTAL","description":"Treatment with Butylphthalide Sodium Chloride Injection begins within 3 hours, administered at 100ml per dose, infused twice daily for a continuous period of 10-14 days.","interventionNames":["Behavioral: Butylphthalide treatment initiation time"]},{"label":"Treatment with Butylphthalide Sodium Chloride Injection begins within 3 hours, administered at 100ml","type":"OTHER","description":"Treatment with Butylphthalide Sodium Chloride Injection begins within 3 hours, administered at 100ml per dose, infused twice daily for a continuous period of 10-14 days.","interventionNames":["Behavioral: Butylphthalide treatment initiation time"]}],"interventions":[{"type":"BEHAVIORAL","name":"Butylphthalide treatment initiation time","description":"Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group (\\&lt;3 hours) and a late initiation group (3-6 hours).","armGroupLabels":["Early initiation group","Treatment with Butylphthalide Sodium Chloride Injection begins within 3 hours, administered at 100ml"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The proportion of participants with an mRS score of 0-2","timeFrame":"90±7 days post-randomization"}],"secondaryOutcomes":[{"measure":"Proportion of participants with an mRS score of 0-1","timeFrame":"90±7 days post-randomization"},{"measure":"Changes in NIHSS scores","timeFrame":"at 6±1 days and 12±2 days compared to baseline"},{"measure":"Proportion of participants with an improvement of ≥4 points in NIHSS scores","timeFrame":"at 6±1 days and 12±2 days"},{"measure":"Early neurological deterioration","timeFrame":"at 24±2 hours and 6±1 days post-randomization"},{"measure":"Proportion of participants with ineffective recanalization","timeFrame":"at 90±7 days post-randomization"},{"measure":"Proportion of participants with recurrent ischemic stroke","timeFrame":"at 90±7 days post-randomization"},{"measure":"Proportion of combined vascular events (recurrent stroke, myocardial infarction, and vascular death)","timeFrame":"at 90±7 days post-randomization"},{"measure":"Difference in cerebral infarction volume size","timeFrame":"between baseline and 12±2 days post-randomization"},{"measure":"Quality of life (EQ-5D) scores","timeFrame":"at 90±7 days post-randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age between 18 and 80 years, gender not specified;\n2. Clinically diagnosed with acute ischemic stroke;\n3. Stroke onset within 3 hours;\n4. NIHSS score at enrollment between 4-25 points, with Item Ia ≤1 point;\n5. Pre-stroke mRS score ≤1 point;\n6. Participants and their representatives capable and willing to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Confirmed intracranial hemorrhage within the past 3 months, including intracerebral hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, and subdural/epidural hematoma;\n2. Known severe hepatic or renal dysfunction or individuals undergoing dialysis for various reasons (severe hepatic dysfunction defined as ALT levels \\&gt;3 times the upper limit of normal or AST levels \\&gt;3 times the upper limit of normal; severe renal dysfunction defined as serum creatinine \\&gt;3.0 mg/dl \\[265.2 μmol/L\\] or glomerular filtration rate \\[GFR\\] \\&lt;30 ml/min/1.73m²);\n3. Systolic blood pressure \\&lt;90 mmHg or \\&gt;220 mmHg;\n4. Presence of bradycardia (heart rate below 60 beats per minute) or sick sinus syndrome;\n5. History of drug or food allergies, including known allergies to the components of the study medication;\n6. Treatment with medications containing Butylphthalide following the onset of the current stroke episode;\n7. Congenital or acquired hemorrhagic disorders, coagulation factor deficiencies, thrombocytopenia, or similar conditions;\n8. Pregnant or breastfeeding individuals, or those planning to become pregnant within the next 90 days;\n9. Severe psychiatric disorders or dementia that preclude understanding of informed consent or compliance with follow-up procedures;\n10. Concurrent malignancy or severe systemic disease with a life expectancy of less than 90 days;\n11. Participation in another interventional clinical study within the last 30 days before randomization, or currently participating in another interventional clinical study;\n12. Any other reason deemed by the investigator as unsuitable for participation in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Le Zhang Zhang","role":"CONTACT","phone":"+8613973187150","email":"zlzdzlzd@csu.edu.cn"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M10543","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M22306","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M2400","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M10282","name":"Infarction","relevance":"LOW"},{"id":"M5793","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5810","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M5204","name":"Brain Diseases","relevance":"LOW"},{"id":"M5742","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17400","name":"Vascular Diseases","relevance":"LOW"},{"id":"M22305","name":"Brain Infarction","relevance":"LOW"},{"id":"M5794","name":"Brain Ischemia","relevance":"LOW"},{"id":"M12284","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000027125","term":"3-n-butylphthalide"}],"ancestors":[{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M353413","name":"3-n-butylphthalide","asFound":"Advocate","relevance":"HIGH"},{"id":"M13865","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M20773","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21869","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}